These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21906872)

  • 21. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
    Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
    Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol.
    Puissant A; Grosso S; Jacquel A; Belhacene N; Colosetti P; Cassuto JP; Auberger P
    FASEB J; 2008 Jun; 22(6):1894-904. PubMed ID: 18245170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
    Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
    Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
    Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
    Jørgensen HG; Allan EK; Mountford JC; Richmond L; Harrison S; Elliott MA; Holyoake TL
    Exp Hematol; 2005 Oct; 33(10):1140-6. PubMed ID: 16219536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function.
    Lin LC; Yeh CT; Kuo CC; Lee CM; Yen GC; Wang LS; Wu CH; Yang WC; Wu AT
    J Agric Food Chem; 2012 Jul; 60(28):7031-9. PubMed ID: 22708678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effect of the anthelmintic drug pyrvinium pamoate on T315I BCR‑ABL‑positive CML cells.
    Zhang J; Jin Y; Pan J
    Mol Med Rep; 2017 Dec; 16(6):9217-9223. PubMed ID: 28990077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukaemia through activating Wnt/β-catenin pathway.
    Huang Y; Yuan C; Liu Q; Wang L
    Clin Exp Pharmacol Physiol; 2022 Dec; 49(12):1334-1341. PubMed ID: 36066385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
    Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
    Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
    Szwed M; Kania KD; Jozwiak Z
    Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.
    Heidel FH; Bullinger L; Feng Z; Wang Z; Neff TA; Stein L; Kalaitzidis D; Lane SW; Armstrong SA
    Cell Stem Cell; 2012 Apr; 10(4):412-24. PubMed ID: 22482506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.